CN115569239A - 一种载万古霉素的材料的制备方法 - Google Patents
一种载万古霉素的材料的制备方法 Download PDFInfo
- Publication number
- CN115569239A CN115569239A CN202211128655.8A CN202211128655A CN115569239A CN 115569239 A CN115569239 A CN 115569239A CN 202211128655 A CN202211128655 A CN 202211128655A CN 115569239 A CN115569239 A CN 115569239A
- Authority
- CN
- China
- Prior art keywords
- diamond
- nano
- vancomycin
- tissue engineering
- loaded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 239000000463 material Substances 0.000 title claims abstract description 21
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 76
- 239000002113 nanodiamond Substances 0.000 claims abstract description 74
- 108010059993 Vancomycin Proteins 0.000 claims abstract description 43
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims abstract description 43
- 229960003165 vancomycin Drugs 0.000 claims abstract description 43
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims abstract description 43
- 210000001519 tissue Anatomy 0.000 claims abstract description 40
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 35
- 239000002131 composite material Substances 0.000 claims abstract description 33
- 239000011521 glass Substances 0.000 claims abstract description 18
- 238000009210 therapy by ultrasound Methods 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 8
- 239000002253 acid Substances 0.000 claims abstract description 7
- 230000002188 osteogenic effect Effects 0.000 claims abstract description 7
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 claims abstract description 5
- 238000012986 modification Methods 0.000 claims abstract description 5
- 230000004048 modification Effects 0.000 claims abstract description 5
- 125000000524 functional group Chemical group 0.000 claims abstract description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 4
- 230000003647 oxidation Effects 0.000 claims abstract description 4
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims description 24
- 238000005516 engineering process Methods 0.000 claims description 18
- 239000002244 precipitate Substances 0.000 claims description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 12
- 238000005303 weighing Methods 0.000 claims description 12
- 238000010146 3D printing Methods 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- 238000011960 computer-aided design Methods 0.000 claims description 9
- 238000004108 freeze drying Methods 0.000 claims description 9
- 238000005406 washing Methods 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 7
- 239000010419 fine particle Substances 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 239000008367 deionised water Substances 0.000 claims description 6
- 229910021641 deionized water Inorganic materials 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 229920001020 poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) Polymers 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 3
- 229920000331 Polyhydroxybutyrate Polymers 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000003462 bioceramic Substances 0.000 claims description 3
- OZSVFZAVFRWFAY-UHFFFAOYSA-N butanoic acid;hexanoic acid Chemical compound CCCC(O)=O.CCCCCC(O)=O OZSVFZAVFRWFAY-UHFFFAOYSA-N 0.000 claims description 3
- 238000013329 compounding Methods 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 3
- 230000000857 drug effect Effects 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- 229910017604 nitric acid Inorganic materials 0.000 claims description 3
- 239000005015 poly(hydroxybutyrate) Substances 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 239000011148 porous material Substances 0.000 claims description 3
- 238000007639 printing Methods 0.000 claims description 3
- 239000011541 reaction mixture Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 abstract description 31
- 230000007547 defect Effects 0.000 abstract description 30
- 230000002458 infectious effect Effects 0.000 abstract description 28
- 244000052616 bacterial pathogen Species 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 8
- 238000011282 treatment Methods 0.000 abstract description 8
- 239000005312 bioglass Substances 0.000 abstract description 7
- 230000008439 repair process Effects 0.000 abstract description 7
- 238000011160 research Methods 0.000 abstract description 7
- 230000035876 healing Effects 0.000 abstract description 5
- 230000033115 angiogenesis Effects 0.000 abstract description 3
- 208000002565 Open Fractures Diseases 0.000 description 3
- 206010031252 Osteomyelitis Diseases 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 208000029534 Infectious Bone disease Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 206010031253 Osteomyelitis acute Diseases 0.000 description 1
- 206010031256 Osteomyelitis chronic Diseases 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 238000011337 individualized treatment Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/08—Carbon ; Graphite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/10—Ceramics or glasses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Ceramic Engineering (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及载万古霉素研究技术领域，且公开了一种载万古霉素的材料的制备方法，包括载万古霉素的纳米金刚石的制备、羧基纳米金刚石的制备、载万古霉素－纳米金刚石－45S5生物玻璃复合组织工程骨的制备；所述纳米金刚石进行超声处理，采用改进的强酸氧化法对其进行功能化修饰，暴露其表面的大量羧基功能基团，与万古霉素的羟基功能基团通过酯键共价结合，制备出载有万古霉素的纳米金刚石。将载万古霉素－纳米金刚石－45S5生物玻璃复合组织工程骨植入感染性骨缺损部位，在感染性骨缺损局部填充的同时缓释万古霉素，抑制常见感染性骨缺损致病菌，并发挥其成骨成血管活性，促进感染性骨缺损的修复和愈合，为感染性骨缺损的修复和治疗提供新的思路和途径。
Description
技术领域
本发明涉及载万古霉素研究技术领域，具体为一种载万古霉素的材料的制备方法。
背景技术
万古霉素(Vancomycin)是一种糖肽类大分子抗生素，其作用机制主要是通过干扰细菌细胞壁结构中的重要组分肽聚糖而阻碍细胞壁的合成，抑制细胞壁中磷脂和多肽的生成而发挥杀菌效果。万古霉素对感染性骨缺损常见的金黄色葡萄球菌、铜绿假单胞菌、肺炎克雷伯菌等革兰氏阳性杆菌和球菌均有杀灭效果，尤其对于有极强耐药性的耐甲氧西林金黄色葡萄球菌具有优异的杀菌作用。但是，全身应用万古霉素易引起听力下降、呼吸抑制甚至肝肾损伤等毒副作用；随着农业、建筑业、制造业以及交通运输业的机械化、自动化高速发展，恶性意外事故的发生以及其导致的各种类型的开放性骨折、骨缺损的治疗变得愈来愈重要，由于严重的高能创伤造成开放性骨折，往往残留异物并伴有神经、血管的损伤，初期清创很难做到完全彻底，残留的感染灶内的细菌会逐渐波及整个骨组织形成急性或者慢性骨髓炎，给后续的治疗带来非常大的困难，开放性骨折迁延不愈而引起的化脓性骨髓炎是骨髓炎中最为凶险的感染性骨疾病，属于骨折后的严重并发症，感染病灶往往位于骨折部位，并逐渐向骨组织的两端蔓延发展，后期往往形成死腔并造成周围软组织的脓肿，死腔和脓肿破溃形成窦道，同时骨坏死、骨不连长期反复发生，最终形成感染性骨缺损，严重的甚至会引起全身性的感染而危及患者生命，从而加大了愈合的难度。
发明内容
(一)解决的技术问题
针对现有技术的不足，本发明提供了一种载万古霉素的材料的制备方法，具备感染性骨缺损的治疗提供新的材料和途径的优点，解决了复合组织工程骨治疗感染性骨缺损的问题。
(二)技术方案
为实现上述目的，本发明提供如下技术方案：一种载万古霉素的材料的制备方法，包括载万古霉素的纳米金刚石的制备、羧基纳米金刚石的制备、载万古霉素－纳米金刚石－45S5生物玻璃复合组织工程骨的制备；
所述纳米金刚石进行超声处理，采用改进的强酸氧化法对其进行功能化修饰，暴露其表面的大量羧基功能基团，然后与万古霉素的羟基功能基团通过酯键共价结合，制备出载有万古霉素的纳米金刚石。
优选的，所述羧基纳米金刚石的制备包含以下步骤：
S101、称取纳米金刚石粉1.2g溶解于150ml去离子水中，3500转/min离心，弃去下层沉淀；
S102、将上层纳米金刚石悬浮液置于小烧杯中冷冻干燥24h，得颗粒较细的纳米金刚石粉末；
S103、称取上述颗粒较细的纳米金刚石粉末200mg加入含25mL混合酸溶液(浓硫酸和浓硝酸的体积比为3∶1)的烧瓶中；
S104、在温度55℃下经过24h后再以10000转/min离心，弃上清液，下层沉淀物依次在NaOH(0.1mol/L)和HCl(0.1mol/L)中85℃加热2.5h；
S105、10000转/min离心，弃上清液，得羧基纳米金刚石，用去离子水洗涤羧基纳米金刚石10次使其近中性；
S106、3000转/min离心，弃下层沉淀物，得上层羧基纳米金刚石悬浮液冷冻干燥24h，得颗粒较细的羧基纳米金刚石粉末备用。
优选的，所述载万古霉素的纳米金刚石的制备包含以下步骤：
S201、称取羧基纳米金刚石120mg于烧瓶中，加入SOCl2 25mL超声溶解后，加入DMF1.2mL，45℃超声3h，75℃加热回流24h；
S202、反应结束后，10000转/min离心反应混合物，下层沉淀物用干燥的THF洗涤5次，30℃真空干燥得羧基纳米金刚石－COCl2；
S203、分别称取羧基纳米金刚石－COCl2 120mg和万古霉素350mg置于烧瓶中；
S204、加入DMF25mL超声溶解，在室温搅拌条件下加入三乙胺1mL；
S205、经10000转/min离心，然后用无水乙醇将下层沉淀洗涤2次，离心得到的沉淀物于50℃下真空干燥24h，得载万古霉素－纳米金刚石；
所述步骤S204中在40℃下超声4h，在60℃条件下反应2天。
优选的，所述载万古霉素－纳米金刚石－45S5生物玻璃复合组织工程骨的制备包含以下步骤：
S301、运用计算机辅助设计(Computer-aided design,CAD)复合组织工程骨的支架模型；
S302、将聚羟基丁酸己酸酯(PHBHHx)用作3D打印中的粘合剂以粘合载药粉末和生物陶瓷；
S303、将PHBHHx粉末溶于氯仿中形成聚合物溶液，将载万古霉素－纳米金刚石与45S5生物活性玻璃的混合物加入溶液中，充分搅拌生成均匀的糊状物；
S304、采用第4代3D-Bioplotter系统(EnvisionTEC,德国)通过施加压缩空气将制备的糊状物打印制备分层多孔复合组织工程骨支架(φ＝6mm×h＝8mm，层间隔600μm)；
S305、分别制备出载万古霉素－纳米金刚石－45S5生物玻璃复合组织工程骨(VNB)，将复合组织工程骨冷冻干燥后置于－20℃备用。
优选的，所述载万古霉素－纳米金刚石－45S5生物玻璃复合组织工程骨运用CAD技术设计出具有合适孔径结构的三维组织工程骨模型，将载万古霉素的纳米金刚石与具有良好生物相容性、成骨活性和可降解性能的45S5生物玻璃混合，利用可在室温下工作的微喷自由成型3D打印技术制备出载万古霉素－纳米金刚石－45S5生物玻璃复合组织工程骨，可最大限度的保证万古霉素的药效。
与现有技术相比，本发明提供了一种载万古霉素的材料的制备方法，具备以下有益效果：
1、该载万古霉素的材料的制备方法，载万古霉素的组织工程材料虽已应用于骨科疾病的研究，但载药效率不尽理想，相比现有的载药缓释系统(如聚乳酸－乙醇酸等)，经过表面修饰的纳米金刚石对于万古霉素有更为高效的载药作用。
2、该载万古霉素的材料的制备方法，将载万古霉素－纳米金刚石－45S5生物玻璃复合组织工程骨植入感染性骨缺损部位，在感染性骨缺损局部填充的同时缓释万古霉素，抑制常见感染性骨缺损致病菌，并发挥其成骨成血管活性，旨在促进感染性骨缺损的修复和愈合，为感染性骨缺损的修复和治疗提供新的思路和途径。
3、该载万古霉素的材料的制备方法，可根据患者感染性骨缺损的药敏结果选择搭载的药物，利用骨组织工程技术、3D打印技术和纳米技术快速制备个性化的复合组织工程骨，有针对性的进行精准的个体化治疗，获得确切的治疗效果，具有重要的科学研究和临床应用意义。
具体实施方式
下面将对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
一种载万古霉素的材料的制备方法，包括载万古霉素的纳米金刚石的制备、羧基纳米金刚石的制备、载万古霉素－纳米金刚石－45S5生物玻璃复合组织工程骨的制备；
所述纳米金刚石进行超声处理，采用改进的强酸氧化法对其进行功能化修饰，暴露其表面的大量羧基功能基团，然后与万古霉素的羟基功能基团通过酯键共价结合，制备出载有万古霉素的纳米金刚石。
进一步的，所述羧基纳米金刚石的制备包含以下步骤：
S101、称取纳米金刚石粉1.2g溶解于150ml去离子水中，3500转/min离心，弃去下层沉淀；
S102、将上层纳米金刚石悬浮液置于小烧杯中冷冻干燥24h，得颗粒较细的纳米金刚石粉末；
S103、称取上述颗粒较细的纳米金刚石粉末200mg加入含25mL混合酸溶液(浓硫酸和浓硝酸的体积比为3∶1)的烧瓶中；
S104、在温度55℃下经过24h后再以10000转/min离心，弃上清液，下层沉淀物依次在NaOH(0.1mol/L)和HCl(0.1mol/L)中85℃加热2.5h；
S105、10000转/min离心，弃上清液，得羧基纳米金刚石，用去离子水洗涤羧基纳米金刚石10次使其近中性；
S106、3000转/min离心，弃下层沉淀物，得上层羧基纳米金刚石悬浮液冷冻干燥24h，得颗粒较细的羧基纳米金刚石粉末备用。
进一步的，所述载万古霉素的纳米金刚石的制备包含以下步骤：
S201、称取羧基纳米金刚石120mg于烧瓶中，加入SOCl2 25mL超声溶解后，加入DMF1.2mL，45℃超声3h，75℃加热回流24h；
S202、反应结束后，10000转/min离心反应混合物，下层沉淀物用干燥的THF洗涤5次，30℃真空干燥得羧基纳米金刚石－COCl2；
S203、分别称取羧基纳米金刚石－COCl2 120mg和万古霉素350mg置于烧瓶中；
S204、加入DMF25mL超声溶解，在室温搅拌条件下加入三乙胺1mL；
S205、经10000转/min离心，然后用无水乙醇将下层沉淀洗涤2次，离心得到的沉淀物于50℃下真空干燥24h，得载万古霉素－纳米金刚石；
所述步骤S204中在40℃下超声4h，在60℃条件下反应2天。
进一步的，所述载万古霉素－纳米金刚石－45S5生物玻璃复合组织工程骨的制备包含以下步骤：
S301、运用计算机辅助设计(Computer-aided design,CAD)复合组织工程骨的支架模型；
S302、将聚羟基丁酸己酸酯(PHBHHx)用作3D打印中的粘合剂以粘合载药粉末和生物陶瓷；
S303、将PHBHHx粉末溶于氯仿中形成聚合物溶液，将载万古霉素－纳米金刚石与45S5生物活性玻璃的混合物加入溶液中，充分搅拌生成均匀的糊状物；
S304、采用第4代3D-Bioplotter系统(EnvisionTEC,德国)通过施加压缩空气将制备的糊状物打印制备分层多孔复合组织工程骨支架(φ＝6mm×h＝8mm，层间隔600μm)；
S305、分别制备出载万古霉素－纳米金刚石－45S5生物玻璃复合组织工程骨(VNB)，将复合组织工程骨冷冻干燥后置于－20℃备用。
进一步的，所述载万古霉素－纳米金刚石－45S5生物玻璃复合组织工程骨运用CAD技术设计出具有合适孔径结构的三维组织工程骨模型，将载万古霉素的纳米金刚石与具有良好生物相容性、成骨活性和可降解性能的45S5生物玻璃混合，利用可在室温下工作的微喷自由成型3D打印技术制备出载万古霉素－纳米金刚石－45S5生物玻璃复合组织工程骨，可最大限度的保证万古霉素的药效。
工作原理：该载万古霉素的材料的制备方法，本项发明采用骨组织工程技术、3D打印技术和纳米技术制备出高效的载万古霉素的纳米金刚石及采用该载药纳米材料的复合组织工程骨(Vancomycin-Nanodiamond-45S5Bioactive glass composite tissueengineering bone,VNB)，将载万古霉素－纳米金刚石－45S5生物玻璃复合组织工程骨植入感染性骨缺损部位，在感染性骨缺损局部填充的同时缓释万古霉素，抑制常见感染性骨缺损致病菌，并发挥其成骨成血管活性，旨在促进感染性骨缺损的修复和愈合，为感染性骨缺损的修复和治疗提供新的思路和途径。远期可根据患者感染性骨缺损的药敏结果选择搭载的药物，利用骨组织工程技术、3D打印技术和纳米技术快速制备个性化的复合组织工程骨，有针对性的进行精准的个体化治疗，获得确切的治疗效果，具有重要的科学研究和临床应用意义；
利用骨组织工程技术、3D打印技术和纳米技术制备的载万古霉素－纳米金刚石－45S5生物玻璃复合组织工程骨，在感染性骨缺损局部填充的同时缓释万古霉素，抑制常见感染性骨缺损致病菌，并发挥其成骨成血管活性，理论上可促进感染性骨缺损的修复和愈合。本发明的研究成果，揭示了载万古霉素－纳米金刚石材料和载万古霉素－纳米金刚石－45S5生物玻璃复合组织工程骨治疗感染性骨缺损的效果和机制，扩展骨组织工程技术、3D打印技术和纳米技术等多种学科技术资源在骨感染相关疾病的研究和应用，为感染性骨缺损的治疗提供新的材料和途径。
尽管已经示出和描述了本发明的实施例，对于本领域的普通技术人员而言，可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型，本发明的范围由所附权利要求及其等同物限定。
Claims (5)
1.一种载万古霉素的材料的制备方法，其特征在于，包括载万古霉素的纳米金刚石的制备、羧基纳米金刚石的制备、载万古霉素－纳米金刚石－45S5生物玻璃复合组织工程骨的制备；
所述纳米金刚石进行超声处理，采用改进的强酸氧化法对其进行功能化修饰，暴露其表面的大量羧基功能基团，然后与万古霉素的羟基功能基团通过酯键共价结合，制备出载有万古霉素的纳米金刚石。
2.根据权利要求1所述的一种载万古霉素的材料的制备方法，其特征在于：所述羧基纳米金刚石的制备包含以下步骤：
S101、称取纳米金刚石粉1.2g溶解于150ml去离子水中，3500转/min离心，弃去下层沉淀；
S102、将上层纳米金刚石悬浮液置于小烧杯中冷冻干燥24h，得颗粒较细的纳米金刚石粉末；
S103、称取上述颗粒较细的纳米金刚石粉末200mg加入含25mL混合酸溶液(浓硫酸和浓硝酸的体积比为3∶1)的烧瓶中；
S104、在温度55℃下经过24h后再以10000转/min离心，弃上清液，下层沉淀物依次在NaOH(0.1mol/L)和HCl(0.1mol/L)中85℃加热2.5h；
S105、10000转/min离心，弃上清液，得羧基纳米金刚石，用去离子水洗涤羧基纳米金刚石10次使其近中性；
S106、3000转/min离心，弃下层沉淀物，得上层羧基纳米金刚石悬浮液冷冻干燥24h，得颗粒较细的羧基纳米金刚石粉末备用。
3.根据权利要求1所述的一种载万古霉素的材料的制备方法，其特征在于：所述载万古霉素的纳米金刚石的制备包含以下步骤：
S201、称取羧基纳米金刚石120mg于烧瓶中，加入SOCl2 25mL超声溶解后，加入DMF1.2mL，45℃超声3h，75℃加热回流24h；
S202、反应结束后，10000转/min离心反应混合物，下层沉淀物用干燥的THF洗涤5次，30℃真空干燥得羧基纳米金刚石－COCl2；
S203、分别称取羧基纳米金刚石－COCl2 120mg和万古霉素350mg置于烧瓶中；
S204、加入DMF25mL超声溶解，在室温搅拌条件下加入三乙胺1mL；
S205、经10000转/min离心，然后用无水乙醇将下层沉淀洗涤2次，离心得到的沉淀物于50℃下真空干燥24h，得载万古霉素－纳米金刚石；
所述步骤S204中在40℃下超声4h，在60℃条件下反应2天。
4.根据权利要求1所述的一种载万古霉素的材料的制备方法，其特征在于：所述载万古霉素－纳米金刚石－45S5生物玻璃复合组织工程骨的制备包含以下步骤：
S301、运用计算机辅助设计(Computer-aided design,CAD)复合组织工程骨的支架模型；
S302、将聚羟基丁酸己酸酯(PHBHHx)用作3D打印中的粘合剂以粘合载药粉末和生物陶瓷；
S303、将PHBHHx粉末溶于氯仿中形成聚合物溶液，将载万古霉素－纳米金刚石与45S5生物活性玻璃的混合物加入溶液中，充分搅拌生成均匀的糊状物；
S304、采用第4代3D-Bioplotter系统(EnvisionTEC,德国)通过施加压缩空气将制备的糊状物打印制备分层多孔复合组织工程骨支架(φ＝6mm×h＝8mm，层间隔600μm)；
S305、分别制备出载万古霉素－纳米金刚石－45S5生物玻璃复合组织工程骨(VNB)，将复合组织工程骨冷冻干燥后置于－20℃备用。
5.根据权利要求4所述的一种载万古霉素的材料的制备方法，其特征在于：所述载万古霉素－纳米金刚石－45S5生物玻璃复合组织工程骨运用CAD技术设计出具有合适孔径结构的三维组织工程骨模型，将载万古霉素的纳米金刚石与具有良好生物相容性、成骨活性和可降解性能的45S5生物玻璃混合，利用可在室温下工作的微喷自由成型3D打印技术制备出载万古霉素－纳米金刚石－45S5生物玻璃复合组织工程骨，可最大限度的保证万古霉素的药效。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211128655.8A CN115569239A (zh) | 2022-09-16 | 2022-09-16 | 一种载万古霉素的材料的制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211128655.8A CN115569239A (zh) | 2022-09-16 | 2022-09-16 | 一种载万古霉素的材料的制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115569239A true CN115569239A (zh) | 2023-01-06 |
Family
ID=84582102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211128655.8A Pending CN115569239A (zh) | 2022-09-16 | 2022-09-16 | 一种载万古霉素的材料的制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115569239A (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110014258A1 (en) * | 2008-02-29 | 2011-01-20 | Smith & Nephew, Inc. | Gradient coating for biomedical applications |
| CN106693061A (zh) * | 2015-07-13 | 2017-05-24 | 中南大学 | 一种聚偏氟乙烯基纳米复合骨支架的制备方法 |
| CN109602951A (zh) * | 2018-11-30 | 2019-04-12 | 重庆医科大学附属永川医院 | 一种可注射的载药脊骨修复材料及其制备方法和使用方法 |
| CN110882398A (zh) * | 2019-12-24 | 2020-03-17 | 辽宁科技学院 | 一种口服姜黄素-纳米金刚石复合物及其制备方法 |
-
2022
- 2022-09-16 CN CN202211128655.8A patent/CN115569239A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110014258A1 (en) * | 2008-02-29 | 2011-01-20 | Smith & Nephew, Inc. | Gradient coating for biomedical applications |
| CN106693061A (zh) * | 2015-07-13 | 2017-05-24 | 中南大学 | 一种聚偏氟乙烯基纳米复合骨支架的制备方法 |
| CN109602951A (zh) * | 2018-11-30 | 2019-04-12 | 重庆医科大学附属永川医院 | 一种可注射的载药脊骨修复材料及其制备方法和使用方法 |
| CN110882398A (zh) * | 2019-12-24 | 2020-03-17 | 辽宁科技学院 | 一种口服姜黄素-纳米金刚石复合物及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cao et al. | New perspectives: In-situ tissue engineering for bone repair scaffold | |
| Tao et al. | Chitosan-based drug delivery systems: from synthesis strategy to osteomyelitis treatment–a review | |
| Lyons et al. | Nanostructured biomaterials for bone regeneration | |
| Mondal et al. | Recent progress on fabrication and drug delivery applications of nanostructured hydroxyapatite | |
| Zheng et al. | Porous bioactive glass micro-and nanospheres with controlled morphology: Developments, properties and emerging biomedical applications | |
| US6511510B1 (en) | Osteoinductive ceramic materials | |
| JP6810331B2 (ja) | 生体活性多孔性骨移植インプラント | |
| Serrano-Aroca et al. | Scaffolds in the microbial resistant era: Fabrication, materials, properties and tissue engineering applications | |
| Erol‐Taygun et al. | Bioactıve glass‐polymer nanocomposites for bone tıssue regeneration applicatıons: a revıew | |
| Mobika et al. | Substantial effect of silk fibroin reinforcement on properties of hydroxyapatite/silk fibroin nanocomposite for bone tissue engineering application | |
| Zheng et al. | Inorganic-based biomaterials for rapid hemostasis and wound healing | |
| Li et al. | Biomimetic membranes of methacrylated gelatin/nanohydroxyapatite/poly (l-lactic acid) for enhanced bone regeneration | |
| US20070254007A1 (en) | Chitosan/nanocrystalline hydroxyapatite composite microsphere-based scaffolds | |
| Zhu et al. | Deformable biomaterials based on ultralong hydroxyapatite nanowires | |
| Zhang et al. | Biodegradable elastic sponge from nanofibrous biphasic calcium phosphate ceramic as an advanced material for regenerative medicine | |
| Kaur et al. | Scaffolds of hydroxyl apatite nanoparticles disseminated in 1, 6-diisocyanatohexane-extended poly (1, 4-butylene succinate)/poly (methyl methacrylate) for bone tissue engineering | |
| Raja et al. | Multifunctional calcium-deficient hydroxyl apatite–alginate core–shell-structured bone substitutes as cell and drug delivery vehicles for bone tissue regeneration | |
| Moris et al. | Preparation and characterization of Pullulan-based nanocomposite scaffold incorporating Ag-Silica Janus particles for bone tissue engineering | |
| Wang et al. | Synthesis and characterization of an injectable and self-curing poly (methyl methacrylate) cement functionalized with a biomimetic chitosan–poly (vinyl alcohol)/nano-sized hydroxyapatite/silver hydrogel | |
| Mota et al. | Polymer nanocomposites used as scaffolds for bone tissue regeneration | |
| Fernandes et al. | Calcium sulfate as a scaffold for bone tissue engineering: a descriptive review | |
| Shuaishuai et al. | Implantable biomedical materials for treatment of bone infection | |
| KR20160136345A (ko) | 기능성 인자를 함유하는 나노 스캐폴드 및 이의 제조방법 | |
| Shi et al. | Synthesis and characterization of an injectable rifampicin-loaded chitosan/hydroxyapatite bone cement for drug delivery | |
| Venkatesan et al. | Chitosan-based polysaccharide biomaterials |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |